TY  - GEN
AU  - Bourlière,Marc
AU  - Rabiega,Pascaline
AU  - Ganne-Carrie,Nathalie
AU  - Serfaty,Lawrence
AU  - Marcellin,Patrick
AU  - Barthe,Yoann
AU  - Thabut,Dominique
AU  - Guyader,Dominique
AU  - Hezode,Christophe
AU  - Picon,Magali
AU  - Causse,Xavier
AU  - Leroy,Vincent
AU  - Bronowicki,Jean Pierre
AU  - Carrieri,Patrizia
AU  - Riachi,Ghassan
AU  - Rosa,Isabelle
AU  - Attali,Pierre
AU  - Molina,Jean Michel
AU  - Bacq,Yannick
AU  - Tran,Albert
AU  - Grangé,Jean Didier
AU  - Zoulim,Fabien
AU  - Fontaine,Hélène
AU  - Alric,Laurent
AU  - Bertucci,Inga
AU  - Bouvier-Alias,Magali
AU  - Carrat,Fabrice
TI  - Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
SN  - 2468-1253
PY  - 2018///0813
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antiviral Agents
KW  - adverse effects
KW  - DNA, Viral
KW  - blood
KW  - Drug Administration Schedule
KW  - Female
KW  - Hepatitis B Surface Antigens
KW  - Hepatitis B e Antigens
KW  - Hepatitis B virus
KW  - genetics
KW  - Hepatitis B, Chronic
KW  - Humans
KW  - Interferon-alpha
KW  - Male
KW  - Middle Aged
KW  - Nucleosides
KW  - Nucleotides
KW  - Patient Reported Outcome Measures
KW  - Polyethylene Glycols
KW  - Recombinant Proteins
KW  - Young Adult
N1  - Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S2468-1253(16)30189-3
ER  -